Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: A planning comparison study

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 3, 2011, Pages 920-926

  Ost, Piet ^a   Speleers, Bruno ^a   De Meerleer, Gert ^a   De Neve, Wilfried ^a   Fonteyne, Valérie ^a   Villeirs, Geert ^a   De Gersem, Werner ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

IMRT; Intensity modulated radiotherapy; Planning; Prostate cancer; Radiotherapy; VMAT; Volumetric arc therapy

Indexed keywords

ARC THERAPY; IMRT; INTENSITY-MODULATED RADIOTHERAPY; PROSTATE CANCER; VMAT;

DISEASES; MAGNETIC RESONANCE IMAGING; PHOTONS; RADIOTHERAPY; RESONANCE;

PHYSICAL THERAPY;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MAXIMUM PERMISSIBLE DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTON; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT PLANNING; VOLUMETRIC ARC THERAPY;

COLON, SIGMOID; FEMUR HEAD; HUMANS; INTESTINE, SMALL; MAGNETIC RESONANCE IMAGING; MALE; ORGANS AT RISK; PHOTONS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER;

EID: 79551500579     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.04.025     Document Type: Article

References (54)

1. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
2. W.U. Shipley, L.J. Verhey, and J.E. Munzenrider Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone Int J Radiat Oncol Biol Phys 32 1995 3 12
3. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial JAMA 294 2005 1233 1239
4. A. Al-Mamgani, W.L. van Putten, and W.D. Heemsbergen Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 980 988
5. N. Cellini, A.G. Morganti, and G.C. Mattiucci Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: Implications for conformal therapy planning Int J Radiat Oncol Biol Phys 53 2002 595 599
6. G. De Meerleer, G. Villeirs, and S. Bral The magnetic resonance detected intraprostatic lesion in prostate cancer: Planning and delivery of intensity-modulated radiotherapy Radiother Oncol 75 2005 325 333
7. G.M. Villeirs, G.O. De Meerleer, and P.J. De Visschere Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A single-institution experience of 356 patients Eur J Radiol Epub 2009 Sept 7
8. P. Puech, E. Potiron, and L. Lemaitre Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: Correlation with radical prostatectomy specimens Urology 74 2009 1094 1099
9. B. Pickett, E. Vigneault, and J. Kurhanewicz Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy Int J Radiat Oncol Biol Phys 44 1999 921 929
10. E.N. van Lin, J.J. Futterer, and S.W. Heijmink IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI Int J Radiat Oncol Biol Phys 65 2006 291 303
11. V. Fonteyne, G. Villeirs, and B. Speleers Intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion Int J Radiat Oncol Biol Phys 72 2008 799 807
12. J. Alvarez Moret, O. Koelbl, and L. Bogner Quasi-IMAT technique and secondary cancer risk in prostate cancer Strahlenther Onkol 185 2009 248 253
13. F. Kjaer-Kristoffersen, L. Ohlhues, and J. Medin RapidArc volumetric modulated therapy planning for prostate cancer patients Acta Oncol 2008 1 6
14. D. Palma, E. Vollans, and K. James Volumetric modulated arc therapy for delivery of prostate radiotherapy: Comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy Int J Radiat Oncol Biol Phys 70 2008 449 455
15. D. Wolff, F. Stieler, and G. Welzel Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer Radiother Oncol 93 2009 226 233
16. M. Iori, G.M. Cattaneo, and E. Cagni Dose-volume and biological-model based comparison between helical tomotherapy and (inverse-planned) IMAT for prostate tumours Radiother Oncol 88 2008 34 45
17. R. Shaffer, W.J. Morris, and V. Moiseenko Volumetric modulated arc therapy and conventional intensity-modulated radiotherapy for simultaneous maximal intraprostatic boost: A planning comparison study Clin Oncol (R Coll Radiol) 21 2009 401 407
18. P. Zhang, L. Happersett, and M. Hunt Volumetric modulated arc therapy: Planning and evaluation for prostate cancer cases Int J Radiat Oncol Biol Phys 76 2010 1456 1462
19. S.F. Kry, M. Salehpour, and D.S. Followill The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy Int J Radiat Oncol Biol Phys 62 2005 1195 1203
20. U. Schneider, A. Lomax, and P. Pemler The impact of IMRT and proton radiotherapy on secondary cancer incidence Strahlenther Onkol 182 2006 647 652
21. M. Cruz, K. Tsuda, and Y. Narumi Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging Eur Radiol 12 2002 357 365
22. G.M. Villeirs, W. Oosterlinck, and E. Vanherreweghe A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer Eur J Radiol 73 2010 352 356
23. G. De Meerleer, L. Vakaet, and S. Meersschout Intensity-modulated radiotherapy as primary treatment for prostate cancer: Acute toxicity in 114 patients Int J Radiat Oncol Biol Phys 60 2004 777 787
24. G. De Meerleer, L. Vakaet, and W. De Gersem Direct segment aperture and weight optimization for intensity-modulated radiotherapy of prostate cancer Strahlenther Onkol 180 2004 136 143
25. G.O. De Meerleer, L.A. Vakaet, and W.R. De Gersem Radiotherapy of prostate cancer with or without intensity modulated beams: A planning comparison Int J Radiat Oncol Biol Phys 47 2000 639 648
26. R.A. Price, G.E. Hanks, and S.W. McNeeley Advantages of using noncoplanar vs. axial beam arrangements when treating prostate cancer with intensity-modulated radiation therapy and the step-and-shoot delivery method Int J Radiat Oncol Biol Phys 53 2002 236 243
27. G.A. Sherouse portable 3D radiotherapy treatment design system Med Phys 16 1989 466
28. W. De Gersem, F. Claus, and C. De Wagter Leaf position optimization for step-and-shoot IMRT Int J Radiat Oncol Biol Phys 51 2001 1371 1388
29. W. Duthoy, W. De Gersem, and K. Vergote Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): First clinical experience Int J Radiat Oncol Biol Phys 57 2003 1019 1032
30. D.P. Dearnaley, E. Hall, and D. Lawrence Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects Br J Cancer 92 2005 488 498
31. A. Pollack, G.K. Zagars, and J.A. Antolak Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial Int J Radiat Oncol Biol Phys 54 2002 677 685
32. V. Fonteyne, W. De Neve, and G. Villeirs Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: The need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity Radiother Oncol 84 2007 156 163
33. T. Bortfeld, R. Schmidt-Ullrich, and W. De Neve Image-Guided IMRT 1st ed. 2006 Springer Berlin
34. S. Webb, and A.E. Nahum A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density Phys Med Biol 38 1993 653 666
35. J.T. Lyman Complication probability as assessed from dose-volume histograms Radiat Res Suppl 8 S13 1985 19
36. G.J. Kutcher, and C. Burman Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method Int J Radiat Oncol Biol Phys 16 1989 1623 1630
37. C. Burman, G.J. Kutcher, and B. Emami Fitting of normal tissue tolerance data to an analytic function Int J Radiat Oncol Biol Phys 21 1991 123 135
38. Y. Kim, and W.A. Tome Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of the entire tumor based on equivalent EUD plans Acta Oncol 47 2008 906 916
39. T.N. Eade, A.L. Hanlon, and E.M. Horwitz What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 68 2007 682 689
40. M.R. Cheung, S.L. Tucker, and L. Dong Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1059 1065
41. W.D. Heemsbergen, A. Al-Mamgani, and M.G. Witte Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): Relationships with local dose, acute effects, and baseline characteristics Int J Radiat Oncol Biol Phys Epub 2010 Jan 5
42. G.J. van der Wielen, J.P. Mulhall, and L. Incrocci Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: A critical review Radiother Oncol 84 2007 107 113
43. L. Perna, C. Fiorino, and C. Cozzarini Sparing the penile bulb in the radical irradiation of clinically localised prostate carcinoma: A comparison between MRI and CT prostatic apex definition in 3DCRT, linac-IMRT and helical tomotherapy Radiother Oncol 93 2009 57 63
44. R.J. Steenbakkers, K.E. Deurloo, and P.J. Nowak Reduction of dose delivered to the rectum and bulb of the penis using MRI delineation for radiotherapy of the prostate Int J Radiat Oncol Biol Phys 57 2003 1269 1279
45. D.J. Brenner, R.E. Curtis, and E.J. Hall Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery Cancer 88 2000 398 406
46. E.J. Hall, and C.S. Wuu Radiation-induced second cancers: The impact of 3D-CRT and IMRT Int J Radiat Oncol Biol Phys 56 2003 83 88
47. H. Aoyama, D.C. Westerly, and T.R. Mackie Integral radiation dose to normal structures with conformal external beam radiation Int J Radiat Oncol Biol Phys 64 2006 962 967
48. W.D. DSouza, and Rosen II Nontumor integral dose variation in conventional radiotherapy treatment planning Med Phys 30 2003 2065 2071
49. A. Pirzkall, M.P. Carol, and B. Pickett The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets Int J Radiat Oncol Biol Phys 53 2002 434 442
50. S.F. Kry, M. Salehpour, and D.S. Followill Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy Int J Radiat Oncol Biol Phys 62 2005 1204 1216
51. J.D. Ruben, S. Davis, and C. Evans The effect of intensity-modulated radiotherapy on radiation-induced second malignancies Int J Radiat Oncol Biol Phys 70 2008 1530 1536
52. D.S. Followill, F. Nusslin, and C.G. Orton Point/counterpoint. IMRT should not be administered at photon energies greater than 10 MV Med Phys 34 2007 1877 1879
53. E.B. Podgorsak, J.A. Rawlinson, and H.E. Johns X-ray depth doses from linear accelerators in the energy range from 10 to 32 MeV AJR Am J Roentgenol Radium Ther Nucl Med 123 1975 182 191
54. S.F. Kry, M. Salehpour, and U. Titt Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy Radiother Oncol 91 2009 132 137